Skip to main content
Premium Trial:

Request an Annual Quote

LifeSpan, Pfizer to Co-develop Automated Pathology System

NEW YORK, March 3 (GenomeWeb News) - LifeSpan BioSciences and Pfizer will co-develop an automated tissue pathology-analysis system for use in preclinical studies, the companies said today.


"The primary goal is to develop a product that Pfizer will use in their research," said Joe Brown, LifeSpan president and CEO.


He said the company would not yet disclose whether the product would be available on the general market, and declined to disclose financial terms of the deal. However, he said that Pfizer would be providing financial support for the project.


Based on LifeSpan's Alias system, the product will use "enhanced image capture and artificial intelligence analysis software to evaluate stained tissue specimens for quality and tissue abnormalities," the companies said.

The Scan

Transcriptomic, Epigenetic Study Appears to Explain Anti-Viral Effects of TB Vaccine

Researchers report in Science Advances on an interferon signature and long-term shifts in monocyte cell DNA methylation in Bacille Calmette-Guérin-vaccinated infant samples.

DNA Storage Method Taps Into Gene Editing Technology

With a dual-plasmid system informed by gene editing, researchers re-wrote DNA sequences in E. coli to store Charles Dickens prose over hundreds of generations, as they recount in Science Advances.

Researchers Model Microbiome Dynamics in Effort to Understand Chronic Human Conditions

Investigators demonstrate in PLOS Computational Biology a computational method for following microbiome dynamics in the absence of longitudinally collected samples.

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.